Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Zisapel explained that the current demand environment is "solid" and not meaningfully changed from the prior quarter, while ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

Walmart's results showcase the nuances of purchasing decisions. Often, consumers don't eliminate a purchase, but shift the ...

If you are looking to expand your investments in AI but want to diversify your portfolio away from chip stocks, I think one ...

MPM BioImpact fully exited its position in Crinetics Pharmaceuticals during the third quarter, a move disclosed in the fund’s ...